- Home
- BRLT vs VERU Comparison
BRLT vs VERU Comparison
Compare BRLT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRLT | VERU |
|---|---|---|
| Founded | 2005 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.6M | 39.8M |
| IPO Year | 2021 | 1990 |
Fundamental Metrics
Financial Performance| Metric | BRLT | VERU |
|---|---|---|
| Price | $1.73 | $2.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.80 | ★ $25.00 |
| AVG Volume (30 Days) | 116.2K | ★ 130.1K |
| Earning Date | 11-05-2025 | 12-16-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $432,597,000.00 | $16,886,419.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | $3.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.31 | ★ 337.24 |
| 52 Week Low | $1.25 | $2.11 |
| 52 Week High | $3.10 | $14.20 |
Technical Indicators
Market Signals| Indicator | BRLT | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 36.52 |
| Support Level | $1.63 | $2.11 |
| Resistance Level | $1.93 | $2.53 |
| Average True Range (ATR) | 0.15 | 0.19 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 15.94 | 40.00 |
Price Performance
Historical ComparisonAbout BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.